Visco-supplement compositions, and methods of use thereof
Visco-supplement compositions derived from a transcellular fluid, such as human amniotic fluid, human aqueous humor fluid, or human vitreous fluid are described. Also described are methods for treating inflammatory conditions of the musculoskeletal system, such as joint inflammation, and methods of lubricating a joint using the described visco-supplement compositions.
1. A visco-supplement composition comprising a processed transcellular fluid, wherein the processed transcellular fluid comprises:
(a) an increased concentration of at least one of a first component selected from the group consisting of proteins, lipids, and carbohydrates as compared to a concentration of the first component in an unprocessed transcellular fluid; and
(b) a decreased concentration of at least one of a second component selected from the group consisting urea, uric acid, and creatinine, as compared to a concentration of the second component in the unprocessed transcellular fluid,
and the composition has a pH in a range of about 6.0 to about 8.0,
wherein the processed transcellular fluid includes 30.25 g/L to 50.375 g/L of proteins, 0.25 g/L to 6.5 g/L of fatty acids, 0.5 g/L to 9.5 g/L of cholesterol, 0.003 g/L to 0.3 g/L of phospholipids, glucose at a concentration of 600 mg/L to 900 mg/L, fructose at a concentration of 48 mg/L to 59 mg/L, hyaluronic acid at a concentration of 30 μg/L to 3600 μg/L,, lubricin at a concentration of 10 μg/ml to 200 μg/ml, no more than 160 mg/L of urea, no more than 80 g/L of uric acid and no more than 14 mg/L of creatinine.
2. The visco-supplement composition according to claim 1 , wherein the unprocessed transcellular fluid is a human transcellular fluid.
3. The visco-supplement composition according to claim 1 , wherein the unprocessed transcellular fluid is selected from the group consisting of an amniotic fluid, aqueous humor fluid, and vitreous humor fluid.
4. The visco-supplement composition according to claim 1 , further comprising a cryoprotectant.
5. The visco-supplement composition according to claim 4 , wherein the cryoprotectant is selected from the group consisting of dimethylsulfoxide (DMSO), glucose, sucrose, glycerol, and combinations thereof.
6. The visco-supplement composition according to claim 1 , wherein the first component is a protein selected from the group consisting of interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor (TNF)-α.
7. The visco-supplement composition according to claim 1 , wherein the first component is a lipid selected from the group consisting of fatty acids, cholesterol, and phospholipids.
8. The visco-supplement composition according to claim 1 , wherein the first component is a carbohydrate selected from the group consisting of glucose, fructose, hyaluronic acid, and lubricin.
9. The visco-supplement composition according to claim 1 , wherein the composition is substantially free of particulate matter.
10. The visco-supplement of claim 1 wherein the processed transcellular fluid includes 48.125 mg/L to 58.625 mg/L of fructose.
11. The visco-supplement of claim 1 wherein the processed transcellular fluid includes 156.25 mg/L to 250 mg/L of lactic acid.
12. The visco-supplement of claim 1 wherein the processed transcellular fluid includes 11 mg/L to 13.4 mg/L of pyruvate.
13. The visco-supplement of claim 1 , wherein the processed transcellular fluid includes at least 329 ng/L of IL-6, at least 421 ng/L of IL-8, at least 3.9 ng/L of IL-10 and at least 11.5 ng/L of TNF-α.